Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Área temáticas
Enfermedades(2)
Farmacología y terapéutica(2)
Fisiología humana(1)
Fisiología y materias afines(1)
Origen
scopus(3)
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
ArticleAbstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in paPalabras claves:Adverse events, Antipsychotic, pharmacogenetics, RisperidoneAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
ArticleAbstract: The variability in the antipsychotic response is, to some extent, genetically determined. Several stPalabras claves:CYP2D6, EFFECTIVENESS, MDR1, pharmacogenetics, Risperidone, SchizophreniaAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusUse of pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6
ArticleAbstract: In bioequivalence studies, intra-individual variability (CV w) is critical in determining sample sizPalabras claves:bioequivalence, Cost, CYP2D6, Genotypes, intra-individual, variabilityAutores:Abad-Santos F., Adrián LLerena, Carcas-Sansuan A., Dorado P., Estévez-Carrizo F.E., González-Vacarezza N., Penãs-Lledó E.M.Fuentes:scopus